SI1883397T1 - Disperzibilne tablete bosertana - Google Patents

Disperzibilne tablete bosertana

Info

Publication number
SI1883397T1
SI1883397T1 SI200630581T SI200630581T SI1883397T1 SI 1883397 T1 SI1883397 T1 SI 1883397T1 SI 200630581 T SI200630581 T SI 200630581T SI 200630581 T SI200630581 T SI 200630581T SI 1883397 T1 SI1883397 T1 SI 1883397T1
Authority
SI
Slovenia
Prior art keywords
dispersible
bosertan
tablet
pyrimidin
benzenesulfonamide
Prior art date
Application number
SI200630581T
Other languages
English (en)
Inventor
Lovelace Holman
Timm Trenktrog
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1883397(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of SI1883397T1 publication Critical patent/SI1883397T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200630581T 2005-05-17 2006-05-15 Disperzibilne tablete bosertana SI1883397T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005005367 2005-05-17
EP06744942A EP1883397B1 (en) 2005-05-17 2006-05-15 Dispersible bosertan tablet

Publications (1)

Publication Number Publication Date
SI1883397T1 true SI1883397T1 (sl) 2010-04-30

Family

ID=37431647

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630581T SI1883397T1 (sl) 2005-05-17 2006-05-15 Disperzibilne tablete bosertana

Country Status (24)

Country Link
US (3) US7959945B2 (sl)
EP (1) EP1883397B1 (sl)
JP (1) JP4219399B2 (sl)
KR (2) KR20100093105A (sl)
CN (1) CN101175484B (sl)
AT (1) ATE451914T1 (sl)
AU (1) AU2006248593B2 (sl)
BR (1) BRPI0610187B8 (sl)
CA (1) CA2607098C (sl)
CY (1) CY1110610T1 (sl)
DE (1) DE602006011150D1 (sl)
DK (1) DK1883397T3 (sl)
ES (1) ES2336943T3 (sl)
HK (1) HK1120212A1 (sl)
IL (1) IL187383A (sl)
MX (1) MX2007014454A (sl)
NO (1) NO339781B1 (sl)
NZ (1) NZ564167A (sl)
PL (1) PL1883397T3 (sl)
PT (1) PT1883397E (sl)
RU (2) RU2404774C2 (sl)
SI (1) SI1883397T1 (sl)
WO (1) WO2006123285A2 (sl)
ZA (1) ZA200710903B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1883397T1 (sl) 2005-05-17 2010-04-30 Actelion Pharmaceuticals Ltd Disperzibilne tablete bosertana
AU2008272685B2 (en) 2007-06-29 2013-04-18 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
US8975402B2 (en) 2008-11-03 2015-03-10 Generics [Uk] Limited HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013169082A1 (ko) 2012-05-11 2013-11-14 한올바이오파마 주식회사 보센탄 제어방출성 경구제제
KR101451327B1 (ko) * 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CN104840965B (zh) * 2015-05-05 2018-05-08 重庆华邦制药有限公司 波生坦的制剂及其稳定剂
KR20160141045A (ko) 2015-05-27 2016-12-08 한올바이오파마주식회사 보센탄을 함유한 약학적 조성물
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108703956A (zh) * 2018-08-21 2018-10-26 天津双硕医药科技有限公司 一种含有波生坦的固体药物组合物
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
WO2023107066A2 (en) * 2021-12-07 2023-06-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Bosentan pharmaceutical compositions
WO2023128902A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising bosentan and relevant excipients
CN114533738A (zh) * 2022-02-19 2022-05-27 苏州海景医药科技有限公司 一种波生坦固体药物组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US6635648B2 (en) * 2000-08-18 2003-10-21 Queen's University At Kingston Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
WO2003101991A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
SI1883397T1 (sl) * 2005-05-17 2010-04-30 Actelion Pharmaceuticals Ltd Disperzibilne tablete bosertana

Also Published As

Publication number Publication date
ES2336943T3 (es) 2010-04-19
NO20076325L (no) 2008-02-04
BRPI0610187A2 (pt) 2010-06-01
BRPI0610187B1 (pt) 2020-03-03
PL1883397T3 (pl) 2010-05-31
EP1883397B1 (en) 2009-12-16
US20080193528A1 (en) 2008-08-14
NZ564167A (en) 2009-12-24
PT1883397E (pt) 2010-02-23
JP4219399B2 (ja) 2009-02-04
RU2007146395A (ru) 2009-06-27
CA2607098A1 (en) 2006-11-23
DK1883397T3 (da) 2010-04-06
MX2007014454A (es) 2008-02-07
ATE451914T1 (de) 2010-01-15
CY1110610T1 (el) 2015-04-29
HK1120212A1 (en) 2009-03-27
US8309126B2 (en) 2012-11-13
RU2010129460A (ru) 2012-01-27
CA2607098C (en) 2012-04-10
KR20080014002A (ko) 2008-02-13
DE602006011150D1 (de) 2010-01-28
NO339781B1 (no) 2017-01-30
US20130023547A1 (en) 2013-01-24
WO2006123285A2 (en) 2006-11-23
US20110245281A1 (en) 2011-10-06
JP2008540512A (ja) 2008-11-20
IL187383A0 (en) 2008-02-09
US7959945B2 (en) 2011-06-14
WO2006123285A3 (en) 2007-07-05
KR20100093105A (ko) 2010-08-24
RU2404774C2 (ru) 2010-11-27
CN101175484A (zh) 2008-05-07
AU2006248593A1 (en) 2006-11-23
IL187383A (en) 2011-09-27
ZA200710903B (en) 2008-12-31
AU2006248593B2 (en) 2011-03-17
CN101175484B (zh) 2012-02-01
EP1883397A2 (en) 2008-02-06
BRPI0610187B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
IL187383A0 (en) Dispersible bosertan tablet
UY29500A1 (es) Proceso quimico
WO2007027238A3 (en) Jak kinase inhibitors and their uses
NO2014029I2 (no) Sofosbuvir. (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)-(fenoksy)fosforylamino)propanoat
AP2004003182A0 (en) Microbicidal pyrimidine or triazine for preventingsexual HIV transmission.
ZA200702656B (en) HIV inhibiting 5-substituted pyrimidines
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
MX2010004576A (es) Derivados de pirimidina novedosos.
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
DE602004032321D1 (de) Die hiv-replikation inhibierende indan-substituierte pyrimidine
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
NZ705225A (en) Process for preparing antiviral compounds
TN2010000070A1 (en) Fused bicyclic pyrimidines
SI1869056T1 (sl) Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
DK2203444T3 (da) Faste former af (S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chlor-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
ZA201002214B (en) 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
TR201903012T4 (tr) Bosentan monohidratın ve bunun ara ürünlerinin hazırlanması için proses.
MX2011005611A (es) Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
AP2157A (en) 2-substituted pyrimidines.
EP2657232A3 (en) Process for the purification of a benzenesulphonamide compound
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
ZA200804599B (en) Aminopyrimidines useful as kinase inhibitors
TW200738720A (en) 7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi